Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162010 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1POLBTP53GAA | |
| SCHEMBL11942479 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1POLBTP53GAA | |
| SCHEMBL11607376 | 0.91 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1POLBTP53GAA | |
| SCHEMBL24290062 | 0.88 | CHRNB2 (0.38) | SMN1; SMN2ALDH1A1POLBTP53SLC6A3 | |
| SCHEMBL5007239 | 0.86 | MEN1 (0.32) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL8292742 | 0.86 | MEN1 (0.32) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL2016829 | 0.85 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1POLBPPM1BPTPN1 | |
| SCHEMBL11087055 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1POLBSLC6A3CCNA2 | |
| SCHEMBL31266111 | 0.82 | MEN1 (0.36) | SLC6A3CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL31266345 | 0.82 | GAA (0.34) | SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| EP-4720076-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. Lundbeck A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| US-12590106-B2 | Spiromacrocyclic orexin 2 receptor agonists | H. LUNDBECK A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| US-20250263422-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2025-08-21 | — | — | US | disclosed |
| US-20240425521-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2024-12-26 | — | — | US | disclosed |
| WO-2024246285-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2024-12-05 | — | — | WO | disclosed |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2019-07-11 | — | — | US | disclosed |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2461683-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8138119-B2 | Alkoxyalkyl spirocyclic tetramic acids and tetronic acids | BAYER CROPSCIENCE AG (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138119-B2 | Alkoxyalkyl spirocyclic tetramic acids and tetronic acids | BAYER CROPSCIENCE AG (DE) | 2012-03-20 | — | — | US | disclosed |
| WO-2011017561-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20090215624-A1 | Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids | BAYER CROPSCIENCE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215624-A1 | Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids | BAYER CROPSCIENCE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| WO-2007048545-A2 | ALKOXYALKYL SPIROCYCLIC TETRAMIC ACIDS AND TETRONIC ACIDS | BAYER CROPSCIENCE AG (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR1 | SMN1; SMN2 2566/4885ALDH1A1 890/4885POLB 4363/4885 |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | SMN1; SMN2 3801/4885ALDH1A1 823/4885POLB 844/4885 |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | SMN1; SMN2 1902/4885ALDH1A1 4545/4885POLB 4062/4885 |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, MCL1, DTYMK | SMN1; SMN2 3801/4885ALDH1A1 823/4885POLB 844/4885 |
| US-20090215624-A1 | Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids | DDT, TBCD, TBCA | SMN1; SMN2 4266/4885ALDH1A1 1790/4885POLB 2658/4885 |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | SMN1; SMN2 1597/4885ALDH1A1 3931/4885POLB 3678/4885 |
| US-12590106-B2 | Spiromacrocyclic orexin 2 receptor agonists | HCRTR2, HCRTR1, OXER1 | SMN1; SMN2 2624/4885ALDH1A1 702/4885POLB 4596/4885 |
| US-20250263422-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | SMN1; SMN2 2101/4885ALDH1A1 1078/4885POLB 4768/4885 |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | SMN1; SMN2 1597/4885ALDH1A1 3931/4885POLB 3678/4885 |
| US-20240425521-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | SMN1; SMN2 2101/4885ALDH1A1 1078/4885POLB 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.